证券代码：300158 证券简称：振东制药 编号：2023-002 特定对象调研 分析师会议 媒体采访 业绩说明会 投资者关系 新闻发布会 路演活动 活动类别 现场参观 其他（请文字说明其他活动内容） 参与单位名称及人 员姓名 投资者网上提问 时 间 2023 年 5 月 11 日（周四）下午 14:00~17:00 地 点 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采 用网络远程的方式召开业绩说明会 总 经 理 杨连民 上市公司接待 董 事 长 李安平 财务总监 刘长禄 人员姓名 董 秘 周红军 公司就投资者在本次说明会中提出的问题进行了回复： 1、贵公司发展方向是正确的，希望公司按着李董指引的 方向发展。希望公司发展成中药百年企业，企业文化也搞得有 声有色，希望企业一路长虹。给股民带来丰厚回报。 答：尊敬的投资者您好！感谢您的肯定。感谢您的关注！ 2、业绩提升的工作内容有什么？ 投资者关系活动主 答：尊敬的投资者您好！公司工作内容主要为：①公司在 要内容介绍 剂型整合、精细化管理的战略指导下，在物料采购、技术改 造、产品引进、质量管理四个方面实现提质增效。②公司紧抓 机遇 ...

证券代码：300158 证券简称：振东制药 | --- | --- | --- | --- | |------------------|--------------------------------|----------------------------|----------| | | | | 2023-001 | | | 特定对象调研 | 分析师会议 | | | | 媒体采访 | 业绩说明会 | | | 投资者关系活动类 | | | | | | 新闻发布会 | 路演活动 | | | 别 | | | | | | 现场参观 | | | | | 其他（请文字说明其他活动内容） | | | | 参与单位名称及人 | | | | | | 线上参与公司 2022 | 年度网上业绩说明会的投资者 | | | 员姓名 | | | | | 时 间 | 2023 年 5 月 5 日 | | | 地 点 进门财经（https://s.comein.cn/ANK5i）平台 董 事 长 李安平 总 经 理 杨连民 上市公司接待人员 独立董事 武 滨 姓名 财务总监 刘长禄 董 秘 周红军 1、①天眼查显示公司持有芦荟清王酒业 5 ...

证券代码：300158 证券简称：振东制药 公告编号：2023-028 山西振东制药股份有限公司 关于参加山西辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，山西振东制药股份有限公司 （以下简称"公司"）将参加由中国证券监督管理委员会山西监管局、 山西省上市公司协会与深圳市全景网络有限公司联合举办的"山西辖 区上市公司 2023 年投资者集体接待日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演" 网站（http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景 路演 APP，参与本次互动交流，活动时间为 2023 年 5 月 11 日（周四） 15:00-17:00。届时公司高管将在线就公司 2022 年度业绩、公司治理、 发展战略、经营状况、融资计划和可持续发展等投资者关心的问题， 与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 山西振东制药股份有限公司董事会 2023 年 5 月 5 日 ...

Financial Performance - The company reported a significant decline in profitability due to the impact of national drug procurement policies, with major products like Bicalutamide capsules experiencing a year-on-year decrease in profitability [4]. - The company's operating revenue for 2022 was ¥3,728,555,341.19, a decrease of 26.80% compared to ¥5,093,776,334.20 in 2021 [26]. - The net profit attributable to shareholders was -¥51,290,041.06 in 2022, representing a decline of 101.96% from ¥2,617,429,564.94 in 2021 [26]. - The net cash flow from operating activities decreased by 69.66% to ¥86,308,195.25 in 2022, down from ¥284,449,199.18 in 2021 [26]. - The total assets at the end of 2022 were ¥6,550,914,912.15, a reduction of 35.10% from ¥10,093,441,565.87 at the end of 2021 [26]. - The company's basic earnings per share for 2022 was -¥0.0499, compared to ¥2.5474 in 2021, marking a decline of 101.96% [26]. - The weighted average return on equity was -0.80% in 2022, down from 38.01% in 2021, a decrease of 38.81% [26]. - The company reported a significant drop in net profit after deducting non-recurring gains and losses, which was -¥148,433,723.12 in 2022 compared to ¥133,863,713.40 in 2021, a decline of 210.88% [26]. - The company received government subsidies amounting to ¥23,064,361.28 in 2022, down from ¥67,764,860.92 in 2021 [33]. Research and Development - R&D expenses increased from 4.29% to 4.78% of operating revenue, reflecting the company's commitment to enhancing its core competitiveness through brand building and product development [4]. - The company has over 130 R&D projects and has undertaken more than 50 national and provincial-level projects, focusing on innovative drugs, generic drugs, and modern traditional Chinese medicine [61]. - The company is focusing on developing products with cost advantages in less competitive therapeutic areas, which may provide good opportunities [40]. - The company has initiated a strategy to expand its OTC product matrix and enhance its e-commerce operations, focusing on dermatological products for high-quality development [67]. - The company has established a risk management mechanism for R&D projects, including regular evaluations by an expert committee [141]. - R&D investment in 2022 amounted to ¥202.66 million, representing 5.44% of operating revenue, an increase from 5.07% in 2021 and 3.77% in 2020 [95]. Market Position and Strategy - The pharmaceutical industry in which the company operates is experiencing favorable conditions, with no signs of overcapacity or technological obsolescence [4]. - The pharmaceutical industry is shifting focus from generic drugs to innovative drugs, indicating a strategic pivot for future growth opportunities [39]. - The company is engaged in the R&D, production, and sales of generic and innovative drugs across various therapeutic areas, including oncology and dermatology [43]. - The company has established a professional sales team and a marketing management model, covering 23 provinces, 5 autonomous regions, and 4 municipalities directly under the central government [47]. - The company has developed an online sales model in collaboration with major platforms like Alibaba, JD.com, and Pinduoduo [50]. - The company is focusing on long-term brand development for products like Dafeixin Minoxidil lotion, which may pressure short-term performance but is expected to enhance competitiveness [4]. Governance and Management - The company maintains independence from its controlling shareholder, ensuring autonomous decision-making in operations [149]. - The company has a structured performance evaluation and incentive mechanism for its board members and senior management [152]. - The company actively engages with stakeholders to balance interests and enhance governance transparency [155]. - The company adheres to legal requirements for corporate governance, ensuring compliance with relevant regulations [147]. - The company reported a total of 2,316,272 shares held by the chairman, with no changes during the reporting period [160]. - The independent director positions were filled by individuals with terms ending in August 2024, indicating stability in governance [160]. Future Outlook - The company has set a future outlook with a revenue guidance of 1.8 billion RMB for the next fiscal year, projecting a growth rate of 20% [173]. - Strategic acquisitions are planned, with a budget of 500 million RMB allocated for potential mergers and acquisitions to enhance product offerings [173]. - The company is investing in new technology research, with a budget of 100 million RMB dedicated to developing advanced drug delivery systems [173]. - The company aims to improve R&D efficiency through collaboration, focusing on innovative drug development and enhancing project management [135]. - The company is committed to expanding its market presence and enhancing its product offerings through strategic initiatives [178]. Employee and Training Initiatives - The company has implemented a training program with a focus on employee development, requiring each employee to complete no less than 120 hours of training annually [196]. - The employee stock ownership plan included 1,759 core employees holding a total of 20,167,608 shares, representing 1.96% of the company's total equity [200]. - The company emphasizes a comprehensive training system with 14 departments and 58 specialties to cultivate skilled talent [196]. - The company has adjusted its salary system to a "three-tier nine-level" structure, enhancing personnel assessment and salary adjustment mechanisms [194]. - The total number of employees at the end of the reporting period was 3,693, with 1,887 in sales, 1,104 in production, and 335 in technical roles [193].

Financial Performance - The company's revenue for Q1 2023 was ¥951,417,159.09, representing a 7.04% increase compared to ¥888,836,734.49 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥394,728.53, a decline of 104.31% from a profit of ¥9,149,858.74 in the previous year[5] - Total operating revenue for Q1 2023 was CNY 951,417,159.09, an increase of 7.06% compared to CNY 888,836,734.49 in the same period last year[21] - Operating profit for Q1 2023 decreased to CNY 7,304,228.83, down 59.5% from CNY 18,066,566.92 in the previous year[21] - The company reported a net loss attributable to shareholders of CNY 16,000,960.16, compared to a loss of CNY 15,606,231.63 in the previous year[19] - The net profit for Q1 2023 was -902,065.90 CNY, a significant decline compared to a net profit of 7,814,690.78 CNY in Q1 2022, representing a decrease of over 111%[22] - The company reported a total comprehensive income of -891,481.36 CNY for Q1 2023, compared to 7,815,211.37 CNY in Q1 2022, marking a decline of over 111%[22] Cash Flow and Investments - The net cash flow from operating activities was -¥221,509,803.49, a decrease of 410.50% compared to ¥71,339,618.63 in the same period last year[11] - The cash inflow from investment activities for Q1 2023 was 2,119,564,208.60 CNY, down from 6,080,578,426.29 CNY in Q1 2022, indicating a decrease of approximately 65%[25] - The cash outflow from investment activities was 1,760,902,169.05 CNY in Q1 2023, compared to 6,593,965,541.13 CNY in Q1 2022, reflecting a decrease of about 73%[25] - The net cash flow from financing activities for Q1 2023 was -110,972,152.16 CNY, compared to -22,104,128.34 CNY in Q1 2022, indicating a worsening situation[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,431,129,004.09, down 1.83% from ¥6,550,914,912.15 at the end of the previous year[5] - Total current assets decreased to CNY 4,761,788,679.00, down 2.5% from CNY 4,883,273,988.04 at the start of the year[19] - Total liabilities decreased to CNY 1,208,729,704.04, a reduction of 8.96% from CNY 1,327,624,130.74 at the beginning of the year[19] - Inventory increased to CNY 1,279,968,680.02, up 19.1% from CNY 1,074,458,576.25 at the beginning of the year[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 74,948[13] - Shanxi Zhendong Health Industry Group Co., Ltd. holds 29.41% of the shares, amounting to 302,230,191 shares[13] - The top ten shareholders include institutional investors and individuals, with the largest being Shanxi Zhendong Health Industry Group Co., Ltd.[13] - The total number of restricted shares held by executives is 3,436,410, with 75,000 shares released during the period[15] - The company reported a total of 51,364,735 shares held by Zhongtai Securities Asset Management, representing 5.00% of the shares[13] - The report indicates that 2,850,000 shares are held by individual shareholder Liu Yubin, with no restrictions[13] - The company has not disclosed any related party relationships among the top shareholders[13] Other Financial Metrics - The company's financial expenses decreased by 135.97% to -¥972,391.69, attributed to a reduction in bank borrowings compared to the previous year[10] - The fair value change income for the period was ¥3,953,915.30, reflecting a substantial increase of 1,326.34% compared to the previous year[10] - The company reported a significant increase in investment income, which rose by 182.19% to ¥9,782,844.63 due to higher financial management returns[10] - Research and development expenses for Q1 2023 were CNY 48,885,568.66, a decrease of 6.1% compared to CNY 51,888,172.00 in Q1 2022[21] - The basic and diluted earnings per share for Q1 2023 were both -0.0004 CNY, compared to 0.0089 CNY in Q1 2022, reflecting a significant decline[22] Reporting Period - The financial report for Q1 2023 is prepared as of March 31, 2023[17] - The report does not mention any new product developments or market expansion strategies[16]

证券代码：300158 证券简称：振东制药 公告编号：2023-024 为做好中小投资者保护工作，增进投资者对公司的了解和认同， 以提升公司治理水平和企业整体价值，现就公司 2022 年度网上业绩 说明会提前向投资者征集相关问题。投资者可于 2023 年 5 月 5 日前 登录网址（https://s.comein.cn/ANK5y）或扫描以下参会二维码进行会 前提问，公司将在 2022 年度网上业绩说明会上，对投资者普遍关注 的问题进行回答。 出席本次年度网上业绩说明会的人员包括：公司董事长李安平先 生、公司独立董事武滨先生、公司总经理杨连民先生、公司财务总监 刘长禄先生和董事会秘书周红军先生。 山西振东制药股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 为了使投资者能够进一步了解公司的生产经营情况，公司拟安排 于 2023 年 5 月 5 日（星期五）15:00～17:00，在"进门财经"举办 2022 年度网上业绩说明会。 投资者可以通过登录网址（https://s.comein.cn/ANK5 ...

证券代码：300158 证券简称：振东制药 编号：2015-001 山西振东制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|------------------------------------|------------------------------------------------------| | | | | | | ☑ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | □ 业绩说明会 | | 投资者关系活动 | □ 新闻发布会 | □ 路演活动 | | 类别 | ☑ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 招商基金管理有限公司：张磊 | | | | | | | 时间 | 2015 年 12 月 10 日 | | | | | | | 地点 | 振东制药公司总部 | | | 上市公司接待人 员姓名 | | 董事会秘书宁潞宏、证券部主任周红军、成员：徐鹏 | | 投资者关系活动 | | 本次投资者关系活动主要有三大内容，主要聚焦在投资 | ...

证券代码：300158 证券简称：振东制药 编号：1 山西振东制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|-----------------------------|-----------------------------------------------------------| | | | | | | √ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | □ 业绩说明会 | | 投资者关系活动 | □ 新闻发布会 | □ 路演活动 | | 类别 | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | | 易方达基金：王俊杰；兴业证券：孙媛媛 | | 时间 | 2016 年 1 月 5 日 | | | 地点 | 山西振东制药股份有限公司 | | | | | | | 上市公司接待人 员姓名 | 李安平 董迷柱 | 李明花 马士锋 宁潞宏 徐根旺 | | 投资者关系活动 | 1 | 、公司自上市以来发生最大规模的融资，是否预示着公司在 | | 主要内 ...

证券代码：300158 证券简称：振东制药 编号：2 | --- | --- | --- | |-----------------------|-------------------------|------------------------------------------------------| | | | | | | | □特定对象调研 □分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活动 | □ | 新闻发布会 √路演活动 | | 类别 | □现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | 参与单位名称及 | 广大投资者 | | | 人员姓名 | | | | 时间 | 2016 年 1 月 29 | 日 | | 地点 | 上海世纪大道 | 1568 号中建大厦 22F 中信证券 04 会议室 | | 上市公司接待人 员姓名 | 李安平 宁潞宏 | 马士锋 徐根旺 | | 投资者关系活动 | 1 . | 复方苦参注射液现在能否完全满足企业生产需求？ | | 主要内容介绍 | | 答：现在完全能满足生产需求，岩舒是我们的独家产品，有 | | | G ...